domingo, 29 de mayo de 2022

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial - The Lancet Regional Health – Western Pacific

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial - The Lancet Regional Health – Western Pacific

No hay comentarios:

Publicar un comentario